Biovest International, Inc.

Minneapolis, MN 55433

SBIR Award Summary

Total Number of Awards 10
Total Value of Awards $0.0
First Award Date 06/01/89
Most Recent Award Date 04/01/98

Key Personnel

Last Name Name Awards Contact
Hirschel Mark D. Hirschel 5
Amiot Bruce Amiot 3
Gramer Michael J Gramer 2

10 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/98 - 03/31/99

Hollow-fiber bioreactor technology is an economical alternative to traditional cell culture methods for the production of cells and cell- derived products, and is finding increased use for novel applications in the fields of tissue engineering, gene therapy, and pharmacology. Hollow-fiber bioreactor...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/28/95 - 09/30/96

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/18/94 - 03/31/95

DESCRIPTION: (Adapted from Applicant's Abstract) The objective of this Phase II project is to further develop a newly designed hollow fiber bioreactor. The applicant claims the bioreactor can support five times more viable mammalian cells/ml than existing hollow fiber bioreactors. The phase I project demonstrated that a bioreactor construct...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/01/94 - 05/31/95

This research will examine growth of normal human marrow in a compact cell culture "OXYCELL" bioreactor. This bioreactor is suited for experimental manipulation due to its small cell volume and in-house manufacture. This research will examine the benefit of providing an adherent substrate in the bioreactor for stromal cell attachment and growt...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/93 - 03/31/94

DESCRIPTION: (Adapted from Applicant's Abstract) The objective of this Phase II project is to further develop a newly designed hollow fiber bioreactor. The applicant claims the bioreactor can support five times more viable mammalian cells/ml than existing hollow fiber bioreactors. The phase I project demonstrated that a bioreactor construct...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/92 - 12/31/93

Therapeutic promise offered by adoptive cellular immunotherapy has focused attention on automated large scale mammalian cell culture instrumentation. One reason for this attention is the enormous logistical difficulties associated with generating sufficient numbers of lymphokine activated killer (LAK) cells, by conventional static culture techn...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/91 - 08/31/92

Therapeutic promise offered by adoptive cellular immunotherapy has focused attention on automated large scale mammalian cell culture instrumentation. One reason for this attention is the enormous logistical difficulties associated with generating sufficient numbers of lymphokine activated killer (LAK) cells, by conventional static culture techn...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/89 - 07/31/90

Recombinant research has facilitated the in vitro production of mmmlian cell secreted products. These products are used in the invitro and in vivo diagnostic and therapeutic setting. Products that have been approved or are in the appr-oval process have projected market needs on the order of 100 kilogram per year. The requirerwnts of large quanti...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/89 - 02/28/90

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 06/01/89 - 11/30/89

Adoptive cellular immunotherapy has recently demonstrated enormous promise as a metastatic cancer treatment. Despite this promise, lymphokine activated killer (LAK) cell therapy has been severely limited by the prohibitive task of in vitro immune cell proliferation. Recently, hollow fiber mammalian cell culture instrumentation has been applied...

Load More